Marla Persky is CEO and President of WOMN LLC, a company dedicated to helping women succeed in the business of law by increasing their knowledge of and acuity with financial drivers, client development, and leadership. Throughout her professional life, Ms. Persky has had the opportunity to understand and practice business principles that lead to personal and company success. Ms. Persky retired in 2013 as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim USA, where she oversaw a department of over 70 individuals. She also was a member of Boehringer’s executive management team and a director of the company and several of its subsidiaries.
Prior to joining Boehringer Ingelheim, Ms. Persky spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her career at Baxter, Ms. Persky managed global legal services, was General Manager of an international medical device business, led international crisis management teams, acquired and integrated international businesses, and designed/implemented strategies to manage global mass torts.
Ms. Persky is currently a member of the board of directors of Revolo Biotherapeutics, a venture funded biotechnology company engaged in the development of therapies that reset the immune system to achieve long-term disease remission. Previously, she served on the board of directors of Cytyc Corporation (Nasdaq listed diagnostics company) Panavance Therapeutics Inc (clinical-stage pharmaceutical company). She was also on the board of Boehringer Ingelheim Corporation, the world’s largest privately owned pharmaceutical company. Ms. Persky was a director of Watermark, Inc., a private publisher and broker of children’s literature.
In addition to her corporate activities, Ms. Persky is on the board of several not-for-profit organizations such as the Leukemia & Lymphoma Society, Primary Stages (an off- Broadway theater company), and the Ridgefield Symphony Orchestra. Ms. Persky is a frequent speaker on a variety of subjects, including leadership principles, mentoring, diversity, crisis management, and negotiation techniques.
Throughout her career, Ms. Persky has focused on improving diversity and inclusion in the legal profession. She has been awarded for her contributions by elite organizations such as the Lawyer's Collaborative for Diversity and the Connecticut Appleseed Foundation. She was recognized as one of the 10 most innovative in-house counsels for her strategy and efforts to increase the opportunities and visibility of women in high-profile litigation
She is a graduate of the Washington University School of Law and Northwestern University.
What is Marla Persky's net worth?
The estimated net worth of Marla Persky is at least $992.58 thousand as of September 11th, 2025. Persky owns 142,000 shares of Xeris Biopharma stock worth more than $992,580 as of December 8th. This net worth approximation does not reflect any other assets that Persky may own. Learn More about Marla Persky's net worth.
How do I contact Marla Persky?
Has Marla Persky been buying or selling shares of Xeris Biopharma?
Marla Persky has not been actively trading shares of Xeris Biopharma during the last ninety days. Most recently, Marla Persky sold 15,500 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $7.72, for a transaction totalling $119,660.00. Following the completion of the sale, the director now directly owns 142,000 shares of the company's stock, valued at $1,096,240. Learn More on Marla Persky's trading history.
Who are Xeris Biopharma's active insiders?
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 8 times. They sold a total of 304,308 shares worth more than $2,181,194.23. The most recent insider tranaction occured on December, 1st when insider Beth Hecht sold 16,667 shares worth more than $116,835.67. Insiders at Xeris Biopharma own 4.6% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 12/1/2025.
